New Lundbeck study of depression drug meets endpoint
Major depressive disorder and dementia often go hand-in-hand, and patients with both who were treated with Trintellix/Brintellix saw improvements in depression symptoms and cognitive performance.
Lundbeck’s depression drug Trintellix/Brintellix (vortioxetine) has met its endpoint in a study involving people with major depressive disorder (MDD) and co-morbid early dementia, the company announces in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
